205 related articles for article (PubMed ID: 30489655)
1. Hypertension induced by serotonin reuptake inhibitors: analysis of two pharmacovigilance databases.
Humbert X; Fedrizzi S; Chrétien B; Sassier M; Bagheri H; Combret S; Drici MD; Le Bas F; Puddu PE; Alexandre J
Fundam Clin Pharmacol; 2019 Jun; 33(3):296-302. PubMed ID: 30489655
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of QT prolongation with serotonin reuptake inhibitors.
Ojero-Senard A; Benevent J; Bondon-Guitton E; Durrieu G; Chebane L; Araujo M; Montastruc F; Montastruc JL
Psychopharmacology (Berl); 2017 Oct; 234(20):3075-3081. PubMed ID: 28770276
[TBL] [Abstract][Full Text] [Related]
3. Reports of sexual disorders related to serotonin reuptake inhibitors in the French pharmacovigilance database: an example of underreporting.
Trenque T; Maura G; Herlem E; Vallet C; Sole E; Auriche P; Drame M
Drug Saf; 2013 Jul; 36(7):515-9. PubMed ID: 23728950
[TBL] [Abstract][Full Text] [Related]
4. Serotonin reuptake inhibitors and hyperprolactinaemia: a case/non-case study in the French pharmacovigilance database.
Trenque T; Herlem E; Auriche P; Dramé M
Drug Saf; 2011 Dec; 34(12):1161-6. PubMed ID: 22077504
[TBL] [Abstract][Full Text] [Related]
5. Role of serotonin and norepinephrine transporters in antidepressant-induced arterial hypertension: a pharmacoepidemiological-pharmacodynamic study.
Montastruc JL; Rousseau V; de Canecaude C; Roussin A; Montastruc F
Eur J Clin Pharmacol; 2020 Sep; 76(9):1321-1327. PubMed ID: 32483650
[TBL] [Abstract][Full Text] [Related]
6. Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database.
Revet A; Montastruc F; Roussin A; Raynaud JP; Lapeyre-Mestre M; Nguyen TTH
BMC Psychiatry; 2020 Jun; 20(1):308. PubMed ID: 32546134
[TBL] [Abstract][Full Text] [Related]
7. Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance Database.
Abadie D; Rousseau V; Logerot S; Cottin J; Montastruc JL; Montastruc F
J Clin Psychopharmacol; 2015 Aug; 35(4):382-8. PubMed ID: 26082973
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.
Sullivan PW; Valuck R; Saseen J; MacFall HM
CNS Drugs; 2004; 18(13):911-32. PubMed ID: 15521793
[TBL] [Abstract][Full Text] [Related]
9. [Antidepressive agents and hypertension: A case/no-case study in French pharmacovigilance database].
Hofferer A; Dolladille C; Chretien B; Sassier M; Laugier D; Atzenhoffer M; Bagheri H; Alexandre J; Fedrizzi S; Humbert X
Encephale; 2022 Aug; 48(4):404-408. PubMed ID: 34311965
[TBL] [Abstract][Full Text] [Related]
10. Drugs and bruxism: A study in the World Health Organization's pharmacovigilance database.
Montastruc JL
Br J Clin Pharmacol; 2023 Dec; 89(12):3765-3768. PubMed ID: 37574820
[TBL] [Abstract][Full Text] [Related]
11. The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France.
Montastruc F; Sommet A; Bondon-Guitton E; Durrieu G; Bui E; Bagheri H; Lapeyre-Mestre M; Schmitt L; Montastruc JL
Eur J Clin Pharmacol; 2012 May; 68(5):767-75. PubMed ID: 22116460
[TBL] [Abstract][Full Text] [Related]
12. Serotonin reuptake inhibitors and breastfeeding: a systematic review.
Orsolini L; Bellantuono C
Hum Psychopharmacol; 2015 Jan; 30(1):4-20. PubMed ID: 25572308
[TBL] [Abstract][Full Text] [Related]
13. A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases.
Chiappini S; Vickers-Smith R; Guirguis A; Corkery JM; Martinotti G; Schifano F
Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631391
[TBL] [Abstract][Full Text] [Related]
14. Exploring the association between selective serotonin reuptake inhibitors and rhabdomyolysis risk based on the FDA pharmacovigilance database.
Wang Y; Lin Y; Lin Q; Liang H; Cai W; Jiang D
Sci Rep; 2023 Jul; 13(1):12257. PubMed ID: 37507539
[TBL] [Abstract][Full Text] [Related]
15. Association of antidepressants plus antithrombotics and bleeding risk: a pharmacovigilance study.
Montastruc JL; Bura-Rivière A
Eur J Clin Pharmacol; 2024 Feb; 80(2):283-285. PubMed ID: 38112734
[TBL] [Abstract][Full Text] [Related]
16. Bleeding adverse drug reactions (ADRs) in patients exposed to antiplatelet plus serotonin reuptake inhibitor drugs: analysis of the French Spontaneous Reporting Database for a controversial ADR.
Maschino F; Hurault-Delarue C; Chebbane L; Fabry V; Montastruc JL; Bagheri H;
Eur J Clin Pharmacol; 2012 Nov; 68(11):1557-60. PubMed ID: 22527341
[TBL] [Abstract][Full Text] [Related]
17. Effect of date of drug marketing on disproportionality measures in pharmacovigilance: the example of suicide with SSRIs using data from the UK MHRA.
Pariente A; Daveluy A; Laribière-Bénard A; Miremont-Salame G; Begaud B; Moore N
Drug Saf; 2009; 32(5):441-7. PubMed ID: 19419238
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of 15 antidepressants on the risk of withdrawal syndrome: A real-world study using the WHO pharmacovigilance database.
Quilichini JB; Revet A; Garcia P; Bouquié R; Hamard J; Yrondi A; Montastruc F
J Affect Disord; 2022 Jan; 297():189-193. PubMed ID: 34699855
[TBL] [Abstract][Full Text] [Related]
19. Selective serotonin reuptake inhibitors and manic switch: A pharmacovigilance and pharmacodynamical study.
Çiray RO; Halaç E; Turan S; Tunçtürk M; Özbek M; Ermiş Ç
Asian J Psychiatr; 2021 Dec; 66():102891. PubMed ID: 34717111
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced immune thrombocytopenia: a descriptive survey in the French PharmacoVigilance database.
Moulis G; Sommet A; Sailler L; Lapeyre-Mestre M; Montastruc JL;
Platelets; 2012; 23(6):490-4. PubMed ID: 22098130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
